Aderis Pharmaceuticals aderis.com


Public lists: Pharma Startups (4732)

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Company (Alive / Active)

Phone: 508-497-2300

Fax:

85 Main Street

Hopkinton, 01748
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aderis Pharmaceuticals $58.8M Aug 10, 2001
See all 31 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aderis Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors

Competitors

Company Status Description Investors

HNC Software

Fallbrook, California, United States
AcquiredHNC Software is a provider of Customer Insight software that enables companies to acquire, manage and retain customers. HNC's decision management and customer analytics technology analyze both structured and unstructured data so companies can derive value from all information. The company's sophisticated software is used in the telecommunications, financial services, insurance and e-commerce industries.Login to see details

Vitae Pharmaceuticals

Fort Washington, Pennsylvania, United States
AcquiredVitae Pharmaceuticals is a clinical stage biopharmaceutical company discovering and developing a portfolio of small molecule compounds that address disease areas, including: chronic kidney disease, diabetes, Alzheimer's disease and atherosclerosis. Vitae's lead compound, VTP-27999, is a potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. Vitae's discovery platform has advantages in creating and analyzing dru...Show allLogin to see details
See all 31 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)